Compare FMN & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FMN | MDXH |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.2M | 68.7M |
| IPO Year | N/A | 2021 |
| Metric | FMN | MDXH |
|---|---|---|
| Price | $10.05 | $0.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $1.80 |
| AVG Volume (30 Days) | 55.7K | ★ 200.4K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $5.40 |
| Revenue Next Year | N/A | $12.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.77 | $0.40 |
| 52 Week High | $11.76 | $5.33 |
| Indicator | FMN | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 37.43 | 44.04 |
| Support Level | $9.77 | $0.51 |
| Resistance Level | $11.32 | $0.64 |
| Average True Range (ATR) | 0.16 | 0.04 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 36.67 | 51.98 |
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.